Cargando…

A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2

The cyclin M (CNNM) family of Mg(2+) transporters is reported to promote tumour progression by binding to phosphatase of regenerating liver (PRL) proteins. Here, we established an assay for detection of the binding between the cystathionine-beta-synthase (CBS) domain of human CNNM3 (a region respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Faji, Huang, Yichen, Wang, Mengqi, Sun, Minxuan, Zhao, Yimeng, Hattori, Motoyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393355/ https://www.ncbi.nlm.nih.gov/pubmed/32733084 http://dx.doi.org/10.1038/s41598-020-69818-x

Ejemplares similares

PRL3 phosphatase active site is required for binding the putative magnesium transporter CNNM3
por: Zhang, Huizhi, et al.
Publicado: (2017)

Erratum: PRL3 phosphatase active site is required for binding the putative magnesium transporter CNNM3
por: Zhang, Huizhi, et al.
Publicado: (2017)

Inhibition of PRL-2·CNNM3 Protein Complex Formation Decreases Breast Cancer Proliferation and Tumor Growth
por: Kostantin, Elie, et al.
Publicado: (2016)

Fluorescence-detection size-exclusion chromatography utilizing nanobody technology for expression screening of membrane proteins
por: Jin, Fei, et al.
Publicado: (2021)

Development and characterization of nanobodies that specifically target the oncogenic Phosphatase of Regenerating Liver-3 (PRL-3) and impact its interaction with a known binding partner, CNNM3
por: Smith, Caroline N., et al.
Publicado: (2023)

Burst kinetics and CNNM binding are evolutionarily conserved properties of phosphatases of regenerating liver
por: Fakih, Rayan, et al.
Publicado: (2023)

Novel Mg (2+) binding sites in the cytoplasmic domain of the MgtE Mg (2+) channels revealed by X-ray crystal structures : Structures of the MgtE cytoplasmic domain
por: Wang, Mengqi, et al.
Publicado: (2023)

CNNM proteins selectively bind to the TRPM7 channel to stimulate divalent cation entry into cells
por: Bai, Zhiyong, et al.
Publicado: (2021)

CNNM2 Heterozygous Variant Presenting as Hypomagnesemia and West Syndrome: Expanding the Spectrum of CNNM2 Gene-Related Epileptic Disorders
por: Panda, Prateek K., et al.
Publicado: (2021)

Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer
por: Radke, I, et al.
Publicado: (2006)

Current Structural Knowledge on the CNNM Family of Magnesium Transport Mediators
por: Giménez-Mascarell, Paula, et al.
Publicado: (2019)

Novel variant in the CNNM2 gene associated with dominant hypomagnesemia
por: García-Castaño, Alejandro, et al.
Publicado: (2020)

Structural basis for the Mg(2+) recognition and regulation of the CorC Mg(2+) transporter
por: Huang, Yichen, et al.
Publicado: (2021)

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019)

Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer
por: Ooki, Akira, et al.
Publicado: (2011)

Novel CNNM2 Mutation Responsible for Autosomal-Dominant Hypomagnesemia With Seizure
por: Tseng, Min-Hua, et al.
Publicado: (2022)

Identification and mechanistic analysis of an inhibitor of the CorC Mg(2+) transporter
por: Huang, Yichen, et al.
Publicado: (2021)

Identification of a Selective RelA Inhibitor Based on DSE-FRET Screening Methods
por: Shiroma, Yoshitomo, et al.
Publicado: (2020)

CNNM2 Mutations Cause Impaired Brain Development and Seizures in Patients with Hypomagnesemia
por: Arjona, Francisco J., et al.
Publicado: (2014)

Structural Insights into the Intracellular Region of the Human Magnesium Transport Mediator CNNM4
por: Giménez-Mascarell, Paula, et al.
Publicado: (2019)

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2021)

CNNM2-Related Disorders: Phenotype and Its Severity Were Associated With the Mode of Inheritance
por: Zhang, Han, et al.
Publicado: (2021)

The phenotypic and genetic spectrum of patients with heterozygous mutations in cyclin M2 (CNNM2)
por: Franken, Gijs A. C., et al.
Publicado: (2021)

Monitoring metal–amyloid-β complexation by a FRET-based probe: design, detection, and inhibitor screening
por: Lee, Hyuck Jin, et al.
Publicado: (2018)

Analysis of molecular determinants of PRL-3
por: Pascaru, Mihaela, et al.
Publicado: (2009)

Drosophila PRL-1 Is a Growth Inhibitor That Counteracts the Function of the Src Oncogene
por: Pagarigan, Krystle T., et al.
Publicado: (2013)

PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021)

Intracellular localization and interaction of mRNA binding proteins as detected by FRET
por: David Gerecht, Pamela S, et al.
Publicado: (2010)

Cyclin M2 (CNNM2) knockout mice show mild hypomagnesaemia and developmental defects
por: Franken, Gijs A. C., et al.
Publicado: (2021)

Novel homozygous nonsynonymous variant of CNNM4 gene in a Chinese family with Jalili syndrome
por: Li, Huajin, et al.
Publicado: (2022)

Src-Mediated Phosphorylation of the Tyrosine Phosphatase PRL-3 Is Required for PRL-3 Promotion of Rho Activation, Motility and Invasion
por: Fiordalisi, James J., et al.
Publicado: (2013)

Depletion of Tissue-Specific Ion Transporters Causes Differential Expression of PRL Targets in Response to Increased Levels of Endogenous PRL
por: Shu, Tingting, et al.
Publicado: (2018)

MiR-130a-3p Inhibits PRL Expression and Is Associated With Heat Stress-Induced PRL Reduction
por: Zhang, Haojie, et al.
Publicado: (2020)

Correction: Monitoring metal–amyloid-β complexation by a FRET-based probe: design, detection, and inhibitor screening
por: Lee, Hyuck Jin, et al.
Publicado: (2019)

Development of FRET‐based high‐throughput screening for viral RNase III inhibitors
por: Wang, Linping, et al.
Publicado: (2020)

Generation of conditional knockout alleles for PRL-3()
por: Yan, Hong, et al.
Publicado: (2011)

DSE-FRET: A new anticancer drug screening assay for DNA binding proteins
por: Miyagi, Toru, et al.
Publicado: (2014)

Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021)

Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening
por: Zhang, Feng-cai, et al.
Publicado: (2019)

Exonuclease III protection assay with FRET probe for detecting DNA-binding proteins
por: Wang, Jinke, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4j4t40ld1bq5unqckri7l9opmk